Market Cap 282.96M
Revenue (ttm) 79.59M
Net Income (ttm) -67.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -84.92%
Debt to Equity Ratio 1.28
Volume 32,000
Avg Vol 36,238
Day's Range N/A - N/A
Shares Out 100.34M
Stochastic %K 10%
Beta 2.86
Analysts Strong Sell
Price Target $7.60

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence,...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 81 69 16 00
Address:
8, rue de la Croix Jarry, Paris, France
focafoca99
focafoca99 Jun. 11 at 7:33 AM
$CLLS shared final Phase 1 data showing 100% response rate for lasme‑cel and promising early results for eti‑cel at the EHA 2026 Congress.
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 10 at 11:58 AM
$CLLS (+5.4% pre) Cellectis receives FDA RMAT designation for blood cancer therapy https://ooc.bz/l/104705
0 · Reply
BananaBrawler
BananaBrawler Jun. 9 at 11:16 PM
$CLLS nice
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 9 at 10:30 PM
CLLS Stock Rallies Over 24% After Hours — Here's Why $CLLS https://stocktwits.com/news/equity/markets/clls-stock-rallies-after-hours-heres-why/cZ0UqzWR7Rq
0 · Reply
topstockalerts
topstockalerts Jun. 9 at 10:16 PM
After Hours Top Gainers PT2 $CLLS $HKPD $HKIT $YYGH $CGTL
0 · Reply
notreload_ai
notreload_ai Jun. 9 at 9:07 PM
$CLLS got FDA RMAT for lasme-cel, an off-the-shelf CAR-T therapy for hard-to-treat leukemia that may speed up patient access. https://notreload.xyz/xy/fda-grants-rmat-to-cellectis-lasme-cel-car-t-therapy/
0 · Reply
Stoxpo
Stoxpo Jun. 9 at 8:35 PM
$CLLS up 13.31% Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL $CLLS $XBI
0 · Reply
SuperGreenToday
SuperGreenToday May. 27 at 12:53 AM
$CLLS Share Price: $3.67 Contract Selected: Nov 20, 2026 $2.5 Calls Buy Zone: $1.99 – $2.46 Target Zone: $3.33 – $4.07 Potential Upside: 58% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
PennyScam
PennyScam May. 20 at 1:30 PM
$CLLS LTC deal is just another frivolous suit. It’s an another he said she said bullshit claim to get at that cash. Argh… Just another money grab eh RK. At the same time there could be some credibility. Licensing can be a fickle thing. It can also be simply adjusted to rectify. This shit happens all the time. I see this as posturing. Someone woke up, saw the glitch with some good hard legal beagle work and here we stand. Cellectis runs a tight ship. I see this as nothing. But Cellectis is my Baby. And no one puts Baby in the corner.
1 · Reply
mikefbi
mikefbi May. 14 at 7:54 PM
$CLLS slow and steady
0 · Reply
Latest News on CLLS
Cellectis (CLLS) Achieves RMAT Designation for CAR-T Therapy

2026-06-09T22:28:41.000Z - 15 days ago

Cellectis (CLLS) Achieves RMAT Designation for CAR-T Therapy


Cellectis initiated with an Overweight at Barclays

2026-05-28T09:25:52.000Z - 4 weeks ago

Cellectis initiated with an Overweight at Barclays

CLLS


Cellectis Slides: Corporate presentation

May 21, 2026, 6:00 AM EDT - 5 weeks ago

Cellectis Slides: Corporate presentation


Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year

2026-05-11T23:35:09.000Z - 6 weeks ago

Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year

CLLS


Cellectis sees cash runway into 4Q27

2026-05-11T23:29:09.000Z - 6 weeks ago

Cellectis sees cash runway into 4Q27

CLLS


Cellectis Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Cellectis Earnings release: Q1 2026


Cellectis Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Cellectis Earnings release: Q1 2026


Cellectis Earnings Call Transcript: Q4 2025

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Cellectis Earnings Call Transcript: Q4 2025


Cellectis Annual report: Q4 2025

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Cellectis Annual report: Q4 2025


Cellectis Earnings release: Q4 2025

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Cellectis Earnings release: Q4 2025


Cellectis Earnings release: Q4 2025

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Cellectis Earnings release: Q4 2025


Cellectis initiated with a Buy at Clear Street

2025-12-22T21:25:12.000Z - 6 months ago

Cellectis initiated with a Buy at Clear Street

CLLS


Cellectis Announces Arbitral Decision in Dispute with Servier

Dec 15, 2025, 4:51 PM EST - 6 months ago

Cellectis Announces Arbitral Decision in Dispute with Servier

CLLS


Cellectis Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 7 months ago

Cellectis Earnings release: Q3 2025


Cellectis reports Q3 adjusted EPS 2c vs (22c) last year

2025-11-07T21:35:35.000Z - 8 months ago

Cellectis reports Q3 adjusted EPS 2c vs (22c) last year

CLLS


Cellectis price target raised to $4 from $3 at Wells Fargo

2025-10-20T10:51:04.000Z - 8 months ago

Cellectis price target raised to $4 from $3 at Wells Fargo

CLLS


Cellectis price target raised to $8 from $4 at Barclays

2025-10-17T09:25:18.000Z - 8 months ago

Cellectis price target raised to $8 from $4 at Barclays

CLLS


Cellectis Transcript: R&D Day 2025

Oct 16, 2025, 8:30 AM EDT - 9 months ago

Cellectis Transcript: R&D Day 2025


Cellectis Press release: FY 2025

Oct 16, 2025, 8:30 AM EDT - 9 months ago

Cellectis Press release: FY 2025


Cellectis Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Cellectis Earnings Call Transcript: Q2 2025


Cellectis Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Cellectis Earnings release: Q2 2025


Cellectis files $200M mixed securities shelf

2025-07-02T20:25:23.000Z - 1 year ago

Cellectis files $200M mixed securities shelf

CLLS


Cellectis Registration statement: Registration Filing

Jul 2, 2025, 8:00 AM EDT - 1 year ago

Cellectis Registration statement: Registration Filing


Cellectis price target lowered to $4 from $5 at Barclays

2025-05-13T08:50:36.000Z - 1 year ago

Cellectis price target lowered to $4 from $5 at Barclays

CLLS


Cellectis Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Cellectis Earnings release: Q1 2025


Cellectis Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Cellectis Earnings release: Q1 2025


Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

Tue, 22 Apr 2025 09:00:17 -0400 - 1 year ago

Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal


Cellectis Earnings Call Transcript: Q4 2024

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Cellectis Earnings Call Transcript: Q4 2024


Cellectis Annual report: Q4 2024

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Cellectis Annual report: Q4 2024


Cellectis Earnings release: Q4 2024

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Cellectis Earnings release: Q4 2024


Cellectis reports Q4 EPS (64c) vs (17c) last year

2025-03-13T22:15:11.000Z - 1 year ago

Cellectis reports Q4 EPS (64c) vs (17c) last year

AZN


Cellectis files to sell 44M ordinary shares for holders

2025-01-15T21:40:16.000Z - 1 year ago

Cellectis files to sell 44M ordinary shares for holders


Cellectis Registration statement: Registration Filing

Jan 15, 2025, 7:00 AM EST - 1 year ago

Cellectis Registration statement: Registration Filing


Cellectis Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Cellectis Earnings Call Transcript: Q3 2024


Cellectis Earnings release: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Cellectis Earnings release: Q3 2024


Cellectis Earnings release: Q2 2024

Aug 6, 2024, 10:30 AM EDT - 2 years ago

Cellectis Earnings release: Q2 2024


Cellectis Earnings Call Transcript: Q1 2024

May 29, 2024, 8:00 AM EDT - 2 years ago

Cellectis Earnings Call Transcript: Q1 2024


Cellectis Earnings release: Q1 2024

May 29, 2024, 8:00 AM EDT - 2 years ago

Cellectis Earnings release: Q1 2024


Cellectis Reports Financial Results for First Quarter 2024

May 28, 2024, 4:30 PM EDT - 2 years ago

Cellectis Reports Financial Results for First Quarter 2024


Cellectis Slides: Corporate Presentation

May 27, 2024, 2:00 AM EDT - 2 years ago

Cellectis Slides: Corporate Presentation


focafoca99
focafoca99 Jun. 11 at 7:33 AM
$CLLS shared final Phase 1 data showing 100% response rate for lasme‑cel and promising early results for eti‑cel at the EHA 2026 Congress.
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 10 at 11:58 AM
$CLLS (+5.4% pre) Cellectis receives FDA RMAT designation for blood cancer therapy https://ooc.bz/l/104705
0 · Reply
BananaBrawler
BananaBrawler Jun. 9 at 11:16 PM
$CLLS nice
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 9 at 10:30 PM
CLLS Stock Rallies Over 24% After Hours — Here's Why $CLLS https://stocktwits.com/news/equity/markets/clls-stock-rallies-after-hours-heres-why/cZ0UqzWR7Rq
0 · Reply
topstockalerts
topstockalerts Jun. 9 at 10:16 PM
After Hours Top Gainers PT2 $CLLS $HKPD $HKIT $YYGH $CGTL
0 · Reply
notreload_ai
notreload_ai Jun. 9 at 9:07 PM
$CLLS got FDA RMAT for lasme-cel, an off-the-shelf CAR-T therapy for hard-to-treat leukemia that may speed up patient access. https://notreload.xyz/xy/fda-grants-rmat-to-cellectis-lasme-cel-car-t-therapy/
0 · Reply
Stoxpo
Stoxpo Jun. 9 at 8:35 PM
$CLLS up 13.31% Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL $CLLS $XBI
0 · Reply
SuperGreenToday
SuperGreenToday May. 27 at 12:53 AM
$CLLS Share Price: $3.67 Contract Selected: Nov 20, 2026 $2.5 Calls Buy Zone: $1.99 – $2.46 Target Zone: $3.33 – $4.07 Potential Upside: 58% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
PennyScam
PennyScam May. 20 at 1:30 PM
$CLLS LTC deal is just another frivolous suit. It’s an another he said she said bullshit claim to get at that cash. Argh… Just another money grab eh RK. At the same time there could be some credibility. Licensing can be a fickle thing. It can also be simply adjusted to rectify. This shit happens all the time. I see this as posturing. Someone woke up, saw the glitch with some good hard legal beagle work and here we stand. Cellectis runs a tight ship. I see this as nothing. But Cellectis is my Baby. And no one puts Baby in the corner.
1 · Reply
mikefbi
mikefbi May. 14 at 7:54 PM
$CLLS slow and steady
0 · Reply
rlkloehn
rlkloehn May. 13 at 8:59 PM
$CLLS On April 20, 2026, Life Technologies Corporation ("LTC"), a subsidiary of Thermo Fisher, claimed to terminate licensing agreements between LTC and Cellectis in 2014, which grant Cellectis non-exclusive rights under certain patents, namely Halle Patent Therapeutic License, Halle Patent Research License and GeneArt and Seamless Cloning Patent Therapeutic License (the "LTC Agreements"). This alleged termination follows TFS's allegations that we did not comply with our obligations under the LTC Agreements, as previously indicated. Simultaneously, LTC brought arbitration proceedings before the American Arbitration Association, designating Cellectis S.A. and Cellectis Bioresearch, Inc. as defendants. LTC's arbitration request alleges that Cellectis violated the LTC Agreements, by underpaying sub-licensing fees and more generally by not complying with our obligations under the LTC Agreements.
1 · Reply
rlkloehn
rlkloehn May. 12 at 6:33 PM
$CLLS Cellectis announced two presentations at the European Hematology Association (EHA) 2026 congress: 🔵 Lasme-cel - Oral presentation | June 13 The full Phase 1 BALLI-01 dataset highlight the promising safety profile and response rates in patients with r/r B-ALL, who have relapsed following multiple prior targeted therapies including autologous CD19 CAR-T. These data form the basis for our pivotal Phase 2 program, currently recruiting in Europe and North America. ➡️ First interim pivotal Phase 2 analysis expected in Q4 2026. 🔵 Eti-cel - Poster presentation | June 13 Early mechanistic insights from the NATHALI-01 study in r/r B-NHL, exploring how lymphodepletion optimization drives cellular expansion and clinical response for our dual-targeting CD20×CD22 allogeneic CAR-T. ➡️ Full Phase 1 data expected in Q4 2026.
0 · Reply
PyroMatic
PyroMatic May. 5 at 4:17 AM
$CLLS watching for bottom.
0 · Reply
rlkloehn
rlkloehn Apr. 28 at 9:09 AM
$CLLS ASGCT abstract 3414 In vivo targeted gene insertion using AAV and LNP formulated TALEN mRNA drives phenylalanine lowering and metabolic rescue in a PKU model 1Alexion Pharmaceuticals, Cambridge, MA, United States, 2Cellectis, New York, NY, United States, 3Astrazeneca 4Cellectis, Paris, France, 5Alexion Pharmaceuticals, Boston, MA, Phenylketonuria (PKU) is caused by inherited deficiency of phenylalanine hydroxylase (PAH), most often due to missense PAH mutations, impairing conversion of phenylalanine to tyrosine. Elevated phenylalanine in blood and brain causes neurotoxicity and developmental impairment. Current standard of care including life-long dietary protein restriction and approved therapies such as sapropterin and pegvaliase are either ineffective or carry black box warnings, underscoring the need for new therapies.
0 · Reply
rlkloehn
rlkloehn Apr. 28 at 2:52 AM
$CLLS Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting May 11-15, in Boston. The data will be presented in a poster: Title: TALE-based epigenetic modulators show sustained knock-down of target genes in T-cells and HEPG2 via a high-throughput multiplex screening platform The abstract is published on the ASGCT website. The poster will be available on Cellectis’ website on the presentation day, Wednesday May 13, 2026 at 5 pm ET.
0 · Reply
rlkloehn
rlkloehn Apr. 23 at 3:08 AM
$CLLS quite the video https://www.linkedin.com/posts/cellectis_car-t-cells-killing-cancer-cells-activity-7452721909844189184-COYR
1 · Reply
PennyScam
PennyScam Apr. 18 at 10:20 PM
$CLLS Great stuff. On the rise. Nice. Crazy K
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Apr. 13 at 1:22 PM
🌅 Watchlist part 2 ✅ $BATL low 4 support, if above 4.20, have potential to 4.50/4.60 ✅ $DEVS .70 support, if above .85, have potential to 1/1.50 ✅ $ATCH low .20 support, if above .30, have potential to .40/.50 ✅ $CLLS low 4 support, still low volume, if above 4.50, have potential to 4.75/5 ✅ $TMDE 1.40 support, if above 1.65, have potential to 1.80/2 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵
0 · Reply
vcaelum
vcaelum Apr. 13 at 12:33 PM
$CLLS lets go 5+ dont hhit my $4 SL pls
0 · Reply
vcaelum
vcaelum Apr. 13 at 12:27 PM
$CLLS was there any updates or something that i missed? got in 4.6. HARD SL at 4, looking for 5+
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 13 at 12:11 PM
$CLLS Thin one
0 · Reply